# US 2025/0017959 A1 · Methods for treating or preventing viral infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0017959 A1
- Document ID: US20250017959A1
- Status: Published application
- Kind: A1
- Application number: 18/708,110
- Filed: 2022-11-07
- Published: 2025-01-16
- Earliest claimed: 2021-11-08
- Assignees: Unikum Therapeutics Aps; Aarhus University
- Applicants: Unikum Therapeutics Aps; Aarhus University
- Inventors: Martin Roelsgaard JAKOBSEN; Renee VAN DER SLUIS; Rasmus Otkjær BAK
- Web page: https://patentgrep.com/patent/US20250017959A1

## CPC

- A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00)
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K 40/19: Dendritic cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/42: Cancer antigens
- A61K 40/46: Viral antigens
- A61P 31/12: Antivirals
- C12N 5/0639: {Dendritic cells, e.g. Langherhans cells in the epidermis}
- A61K 2035/122: {for inducing tolerance or supression of immune responses}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2506/11: from blood or immune system cells
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to methods for treating or preventing viral infection, or disease or complications associated with viral infection, in particular infection by a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV.

## Claims

### Claim 1

A method of treating or preventing a disease in a subject comprising administering a plasmacytoid dendritic cell (pDC), or a composition comprising said cell, to the subject, wherein the disease is a viral infection, or a disease or complication associated with a viral infection.

### Claim 2 (depends on 1)

The method of claim 1, wherein:
(a) the method additionally comprises administration of an anti-viral and/or anti-inflammatory agent;
(b) the pDC is unable to express IL-6 or exhibits reduced IL-6 expression; and/or
(c) the pDC exhibits reduced or no CD304 expression.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein said pDC is engineered by transformation with an exogenous construct which prevents or reduces IL-6 expression by the pDC.

### Claim 4 (depends on 3)

The method of claim 3, wherein IL-6 expression by the pDC is prevented or reduced by deletion or disruption of TLR2.

### Claim 5

The method of any one of the preceding claims, wherein the pDC is engineered by transformation with an exogenous construct which deletes or disrupts CD304.

### Claim 6

The method of any one of the preceding claims, wherein the anti-viral and/or anti-inflammatory agent is administered simultaneously with the pDC, or at a suitable time interval subsequent to administration of the pDC; optionally wherein the time interval is at least around 4 hours, 8 hours, 12 hours, or 24 hours.

### Claim 7

The method of any one of the preceding claims, wherein the anti-inflammatory agent is:
(a) An IL-6 antagonist; optionally comprising an antibody specific for IL-6 or IL-6R, such as tocilizumab, sarilumab, siltuximab, sirukumab, clazakizumab, elsilimomab, or levilimab;
(b) A corticosteroid, such as dexamethasone, hydrocortisone or methylprednisolone;
(c) A non-steroidal anti-inflammatory drug (NSAID), such as ibuprofen.

### Claim 8

The method of any one of the preceding claims, wherein the virus is a coronavirus or influenza virus, optionally SARS-CoV-2, SARS-CoV or MERS-CoV, optionally wherein the disease is COVID-19.

### Claim 9

The method of any one of the preceding claims, wherein the pDC is a stem cell-derived pDC.

### Claim 10

The method of any one of the preceding claims, wherein the pDC expresses IFN type I and/or IFN type III cytokines.

### Claim 11

A pDC, or a composition comprising said cell, as defined in any one of the preceding claims, optionally for use in a method of treating or preventing a viral infection or a disease or complication associated with a viral infection.

### Claim 12 (depends on 11)

A pharmaceutical composition comprising the pDC of claim 11 and a pharmaceutically acceptable preservative, diluent, excipient, or carrier.

### Claim 13 (depends on 7, 11, 12)

The composition of claim 11 or 12, additional comprising an anti-inflammatory agent, optionally an anti-inflammatory agent as defined in claim 7.

### Claim 14

A method of generating a composition comprising a pDC comprising:
(a) providing hematopoietic stem progenitor cells (HSPCs);
(b) incubating said HSPCs in one or more media comprising cytokines, growth factor and/or interferons (IFNs), whereby said HSPCs are differentiated into precursor-pDCs and into pDCs incubating said HSPCs in one or more media, which media may comprise one or more cytokines, growth factors, interferons (IFNs) and/or aryl hydrocarbon receptor (1) antagonists (such as stemregenin-1), whereby said HSPCs are differentiated into precursor-pDCs and into pDCs; and
(c) transforming said HSPCs prior to differentiation, or transforming said pDCs subsequent to differentiation, with an exogenous construct which prevents or reduces IL-6 expression or which prevents or reduces CD304 expression.

### Claim 15 (depends on 14)

The method of claim 14, which further comprises formulating the pDC with a pharmaceutically acceptable preservative, diluent, excipient, or carrier.

### Claim 16 (depends on 14, 15)

The method of any one of claims 14 or 15, wherein the HSPCs are harvested from a sample obtained from a subject in need of treatment for or prevention of a disease, wherein the disease is a viral infection, or a disease or complication associated with a viral infection.
